The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×3•Originally published 22 April 2026•Updated 22 April 2026•

1 min read

AbbVie to Invest $1.4 Billion in New North Carolina Manufacturing Campus

Key Facts

1AbbVie announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina.

2The new campus will create 734 jobs to support production of AbbVie's immunology, neuroscience, and oncology medicines.

about 1 month ago

Version History

Version 3about 1 month ago

What changed: Specified the precise location of the new facility near the Research Triangle Park, a major pharmaceutical hub.

Version 2about 1 month ago

What changed: The update specifies the integration of AI and advanced laboratory technologies into the new manufacturing campus's operations.

Version 1about 1 month ago

What changed: Confirmed the timing of the announcement (Wednesday) and explicitly categorized the project as the company's largest single-site investment to date.

Global pharmaceutical giant AbbVie has confirmed a $1.4 billion investment to develop a state-of-the-art manufacturing campus in Durham, North Carolina, specifically located near the prestigious Research Triangle Park area. This project marks AbbVie's largest-ever single-site investment, supported by a $26 million incentive package approved by North Carolina officials. The facility is part of a broader $100 billion commitment to U.S. research and development, aimed at scaling production for critical medicines in immunology, neuroscience, and oncology. Spanning 185 acres, the campus is expected to create 734 new jobs and significantly boost the company's global operational footprint. Construction is scheduled to begin in 2026, with completion targeted for late 2028, positioning the company within a major global pharmaceutical hub.